PolyPid regains Europe rights: what it means for PolyPid stock

Published on 10/02/2026 at 20:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

EMA validation starts formal review of D-PLEX100 on October 1, 2026. For PolyPid stock, this means an FDA decision on November 28, 2026.

PYPD, IL0011326795, Illustration mit AI erstellt.

PolyPid (ISIN IL0011326795) regained exclusive European commercialization rights for D-PLEX100 on October 1, 2026, after ending its agreement with ADVANZ PHARMA. GlobeNewswire reported that the rights reverted to PolyPid after the 2022 European license, distribution and supply agreement was mutually terminated.

Europe rights return to PolyPid

The move gives PolyPid control of European commercialization while its North American partner, Azurity Pharmaceuticals, covers the United States and Canada. That creates a broader commercialization path for D-PLEX100, but it also places more responsibility for European development and market execution with PolyPid.

On the regulatory side, the European Medicines Agency validated PolyPid's marketing authorization application on October 1, 2026, beginning formal review by the Committee for Medicinal Products for Human Use. The application was submitted on September 14, 2026, under the centralized procedure. GlobeNewswire said the application is supported by the Phase 3 SHIELD II trial.

Clinical data carry the case

SHIELD II showed a 60.00 percent relative risk reduction in surgical site infections versus standard of care, with a p-value of 0.0013, according to the October 1 release. D-PLEX100 is designed to release doxycycline locally at the surgical site for 30 days, giving the product a defined clinical and commercial proposition.

The regulatory calendar is the next major test. The U.S. Food and Drug Administration accepted the New Drug Application for Priority Review with a November 28, 2026, PDUFA goal date, while the EMA process now provides a second regulatory path. StockTitan published the related Form 6-K and identified the 60.00 percent trial reduction and the November 28, 2026, FDA date.

Losses remain part of the picture

PolyPid's second-quarter 2026 earnings per share were negative USD 0.35 versus a consensus estimate of negative USD 0.38, as reported by Markets Insider on October 1, 2026. The comparison shows that the investment case still depends on regulatory progress and eventual commercialization rather than current earnings power.

Nasdaq quote and market value

PolyPid was trading intraday at USD 5.11 on Nasdaq on October 2, 2026, at 2:13 p.m. EDT, down 4.84 percent from the prior close of USD 5.37. The stock's 52-week range was USD 3.06 to USD 5.73, while market capitalization stood at USD 97.5 million on the same date.